Drug Metabolism Letters

Author(s): Judit Morello, Sonia Rodriguez-Novoa, Inmaculada Jimenez-Nacher and Vincent Soriano

DOI: 10.2174/187231207779814256

Cite As
Drug Interactions of Tipranavir, a New HIV Protease Inhibitor

Page: [81 - 84] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Tipranavir is one of the latest approved HIV protease inhibitors. This non-peptidic molecule is an strong inducer of cytochrome P450 and has to be co-administered with low doses ritonavir as pharmacokinetic booster to achieve effective antiviral activity in vivo. As expected, significant drug interactions may occur in patients treated with tipranavir/ ritonavir, including diminished exposure to some antiretroviral agents. Although a few interactions can be managed with adequate drug dosing others preclude to use these medications in combination.

Keywords: Tipranavir, HIV, drug interactions, protease inhibitors